跳至主要内容
临床试验/NCT07384793
NCT07384793进行中(未招募)4 期

Comparison of Efficacy of Azithromycin Alone vs Combination of Azithromycin and Probiotics in Management of Mild to Moderate Acne Vulgaris

Hayatabad Medical Complex1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2025年10月12日最近更新:
干预措施

试验速览

阶段
4 期
状态
进行中(未招募)
入组人数
60
试验地点
1
主要终点
Reduction of Acne Lesion Count as per Acne Global assessment scale

研究概览

简要总结

The Goal of this Clinical trial is to compare the efficacy of oral azithromycin alone with combination therapy of oral azithromycin and probiotics to see is there any significant difference in outcome of two treatment modalities in mild to moderate acne vulgaris

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
15 Years 至 35 Years(Child, Adult)
性别
All
接受健康志愿者

入选标准

  • Participants with mild to moderate acne on basis of global acne assessment scale score of 2 or 3 and with 20 to 50 total lesion count will be included.

排除标准

  • History of active localized or generalized infection History of autoimmune disease History of other facial skin diseases/ excessive facial hair or scars History of using isotretinoin or oral contraceptive pills in past 6 months History of already using antibiotics for acne treatment History of facial cosmetic procedures within last 3 months History of allergy to drugs used in study History of using drugs that may interact with azithromycin Currently pregnant or lactating women

研究组 & 干预措施

Oral Azithromycin group

Active Comparator

The participants in this arm of study will receive only Oral Azithromycin to treat their Acne

干预措施: Azithromycin 250 MG Oral Capsule (Drug)

Oral Azithromycin and Oral probiotic combination

Active Comparator

The participants in this arm of study will receive both Oral Azithromycin and Oral Probiotics to treat their Acne

干预措施: Azithromycin 250 MG Oral Capsule Along with Oral Probiotics (Drug)

结局指标

主要结局

Reduction of Acne Lesion Count as per Acne Global assessment scale

时间窗: 12 Weeks

The patients will be assessed before and after the treatment and their lesions will be counted .The Primary outcome that will be measured is the reduction of the lesion counts according to the Acne global Assessment scale The participants included will be with mild to moderate acne on basis of global acne assessment scale score of 2 or 3. The minimum Lesion count considered will be 20 and the Maximum will be 50. Lower is better Higher is worse.

次要结局

未报告次要终点

研究者

申办方类型
Other Gov
责任方
Principal Investigator
主要研究者

Naheed asghar

Associate Professor Dermatology unit HMC

Hayatabad Medical Complex

研究点 (1)

Loading locations...

相似试验